Low prevalence of diagnosed asthma in Greenland – a call for increased focus on diagnosing

Figures & data

Table 1. Basic characteristics of patients in Nuuk vs. from the remaining parts of Greenland.

	Nuuk					The remaining parts of Greenland					Nuuk		The remaining parts of Greenland
	Women		Men			Women		Men			Total		Total
	Mean (SD)	N	Mean (SD)	N	p	Mean (SD)	N	Mean (SD)	N	p	Mean (SD)	N	Mean (SD)	N	p
Age (years)	49 (15.5)	385	47 (16.8)	155	0.493	49 (17.3)	234	44 (20.8)	96	<0.05	48 (15.9)	540	48 (18.5)	330	0.576
Weight (kg)	77 (18.0)	370	88 (21.7)	137	<0.001	78 (20.0)	206	82 (22.6)	75	0.165	80 (19.7)	507	79 (20.8)	281	0.502
Height (cm)	160 (7.0)	363	174 (10.1)	136	<0.001	158 (6.6)	194	169 (9.6)	75	<0.001	164 (10.0)	499	161 (8.9)	269	<0.001
BMI (kg/m^2)	30 (6.6)	352	30 (5.8)	129	0.337	31 (7.5)	185	29 (6.9)	66	<0.05	30 (6.4)	481	31 (7.4)	251	0.100
FEV1 (L)	2 (0.7)	336	3 (1.0)	132	<0.001	2 (0.7)	160	3 (1.0)	65	<0.001	2.6 (0.9)	468	2.4 (0.9)	225	<0.05
FEV1%*	90 (17.8)	334	86 (21.6)	130	0.057	90 (21.1)	157	87 (19.5)	64	0.287	89 (19.0)	464	89 (20.6)	221	0.845
FVC (L)	3 (0.8)	336	4 (1.2)	132	<0.001	3 (0.7)	159	4 (1.2)	64	<0.001	3.5 (1.1)	468	3.3 (1.1)	223	<0.05
FVC%*	95 (16.0)	336	94 (17.3)	132	0.334	98 (20.3)	157	100 (17.5)	63	0.529	95 (16.3)	468	98 (19.5)	220	<0.05
FEV1/FVC%	75 (9.4)	334	72 (11.6)	129	<0.001	75 (9.99)	159	70 (11.6)	64	<0.01	75 (10.2)	463	73 (10.6)	223	0.158

P values below 0.05 are in bold. * percent of predicted values based on European reference. FVC= Forced Vital Capacity, FEV1=Forced Expiratory Volume in first second.

Table 2. Age-specific prevalence (%) among women and men in Nuuk vs. from the remaining parts of Greenland.

	Nuuk			The remaining parts of Greenland			Nuuk	The remaining parts of Greenland
	Women	Men		Women	Men		Total	Total
	(95% CI) (n/N)	(95% CI) (n/N)	p	(95% CI) (n/N)	(95% CI) (n/N)	p	(95% CI) (n/N)	(95% CI) (n/N)	p
Prevalence (%) among patients ≥ 12 years of age	5.0 (4.49–5.46) (385/7,736)	1.8 (1.51–2.07) (155/8,669)	<0.001	1.6 (1.40–1.81) (234/14,607)	0.7 (0.54–0.82) (96/14,120)	<0.001	3.3 (3.02–3.56) (540/16,405)	1.1 (1.02–1.26) (330/28,908)	<0.001
Prevalence (%) in age groups
12–19 years	1.8 (0.91–2.64) (16/900)	1.5 (0.71–2.24) (14/950)	0.605	0.9 (0.46–1.34) (16/1,777)	1.1 (0.65–1.58) (22/1,967)	0.506	1.6 (1.05–2.20) (30/1,850)	1.0 (0.69–1.34) (38/3,744)	0.051
20–29 years	2.7 (1.88–3.53) (40/1,478)	0.8 (0.35–1.25) (12/1,502)	<0.001	0.9 (0.55–1.30) (23/2,482)	0.4 (0.12–0.58) (9/2,581)	<0.01	1.7 (1.27–2.22) (52/2,980)	0.6 (0.41–0.85) (32/5,063)	<0.001
30–39 years	3.1 (2.32–3.95) (55/1,756)	1.1 (0.65–1.61) (21/1,861)	<0.001	1.0 (0.63–1.44) (25/2,410)	0.4 (0.14–0.61) (10/2,664)	<0.01	2.1 (1.63–2.57) (76/3,617)	0.7 (0.46–0.92) (35/5,074)	<0.001
40–49 years	5.2 (3.93–6.56) (58/1,106)	2.1 (1.35–2.83) (30/1,434)	<0.001	1.5 (0.98–1.97) (34/2,301)	0.9 (0.39–1.40) (12/1,338)	0.131	3.5 (2.75–4.18) (88/2,540)	1.3 (0.90–1.63) (46/3,639)	<0.001
50–59 years	8.5 (7.02–10.04) (112/1,313)	2.7 (1.89–3.53) (41/1,514)	<0.001	3.1 (2.43–3.79) (77/2,476)	0.7 (0.36–1.06) (16/2,257)	<0.001	5.4 (4.58–6.25) (153/2,827)	1.7 (1.37–2.07) (93/5,409)	<0.001
60–69 years	8.7 (6.82–10.55) (76/875)	2.3 (1.36–3.15) (24/1,064)	<0.001	1.7 (1.13–2.32) (32/1,856)	0.7 (0.38–1.05) (17/2,378)	<0.01	5.2 (4.17–6.14) (100/1,939)	1.2 (0.84–1.48) (49/4,234)	<0.001
70–79 years	11.2 (7.19–15.12) (27/242)	4.2 (1.89–6.59) (12/283)	<0.01	2.1 (1.19–2.93) (21/1,019)	1.0 (0.25–1.68) (7/726)	0.072	7.4 (5.19–9.67) (39/525)	1.6 (1.02–2.19) (28/1,745)	<0.001
80+ years	1.5 (−1.43–4.46) (1/66)	1.6 (−1.55–4.83) (1/61)	0.955	2.1 (0.44–3.76) (6/286)	1.4 (−0.18–3.05) (3/209)	0.586	1.6 (0.59–3.74) (2/127)	1.8 (0.64–3.00) (9/495)	0.853

n/N, number of patients/population. P values below 0.05 are in bold.

Table 3. Quality of care (%) among women and men in Nuuk vs. from the remaining parts of Greenland.

	Nuuk			The remaining parts of Greenland			Nuuk	The remaining parts of Greenland
	Women	Men		Women	Men		Total	Total
	(95% CI) (n/N)	(95% CI) (n/N)	p	(95% CI) (n/N)	(95% CI) (n/N)	p	(95% CI) (n/N)	(95% CI) (n/N)	p
Process indicators within the previous two years, % (n/N)
- Patients in whom smoking status was assessed - Patients in whom spirometry was performed	84.4 (80.79–88.04) (325/385) 82.6 (78.81–86.38) (318/385)	78.7 (72.27–85.15) (122/155) 80.7 (74.43–86.86) (125/155)	0.112 0.593	63.3 (57.07–69.43) (148/234) 59.4 (53.11–65.69) (139/234)	58.3 (48.47–68.20) (56/96) 60.4 (50.63–70.20) (58/96)	0.404 0.864	82.8 (79.59–85.96) (447/540) 82.0 (78.80–85.27) (443/540)	61.8 (56.58–67.06) (204/330) 59.7 (54.40–64.99) (197/330)	<0.001 <0.001
- Patients in whom BMI was measured	89.4 (86.27–92.43) (344/385)	87.1 (81.82–92.37) (135/155)	0.454	47.0 (40.61–53.40) (110/234)	69.8 (60.61–78.98) (67/96)	0.027	88.7 (86.03–91.37) (479/540)	75.8 (71.13–80.38) (250/330)	<0.001
Proximal outcome indicator within the previous two years, % (n/N)
- Patients who were current smokers	40.6 (35.28–45.95) (132/325)	31.2 (22.93–39.37) (38/122)	0.066	45.3 (37.25–53.29) (67/148)	37.5 (24.82–50.18) (21/56)	0.317	38.0 (33.53–42.53) (170/447)	43.1 (36.34–49.93) (88/204)	0.217

n/N, number of patients/population. P values below 0.05 are in bold.